Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy-Reference-Cited by-同舟云学术

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy

Published:2021-06-05 Issue:6 Volume:110 Page:1435-1454
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Baranello Giovanni¹²,Gorni Ksenija³,Daigl Monica³,Kotzeva Anna³,Evans Rachel⁴,Hawkins Neil⁵,Scott David A.⁴,Mahajan Anadi⁵,Muntoni Francesco¹⁶,Servais Laurent⁷⁸

Affiliation:

1. Dubowitz Neuromuscular Centre UCL Great Ormond Street Institute of Child Health London United Kingdom

2. Developmental Neurology Unit Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologico Carlo Besta Milan Italy

3. F. Hoffmann‐La Roche Ltd Basel Switzerland

4. Visible Analytics Oxford UK

5. Bridge Medical Consulting Ltd London UK

6. National Institute for Health Research Biomedical Research Centre University College of London Great Ormond Street Institute of Child Health Great Ormond Street Hospital National Health Service Trust London UK

7. Division of Child Neurology Reference Center for Neuromuscular Disease Department of Pediatrics Centre Hospitalier Régional de Références des Maladies Neuromusculaires University Hospital Liège & University of La Citadelle Liège Belgium

8. Department of Paediatrics Muscular Dystrophy UK Oxford Neuromuscular Centre University of Oxford Oxford UK

Funder

Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2247

Reference98 articles.

1. The Genetics of Spinal Muscular Atrophy: Progress and Challenges

2. Identification and characterization of a spinal muscular atrophy-determining gene